JPWO2022129512A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022129512A5 JPWO2022129512A5 JP2023537140A JP2023537140A JPWO2022129512A5 JP WO2022129512 A5 JPWO2022129512 A5 JP WO2022129512A5 JP 2023537140 A JP2023537140 A JP 2023537140A JP 2023537140 A JP2023537140 A JP 2023537140A JP WO2022129512 A5 JPWO2022129512 A5 JP WO2022129512A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bifunctional molecule
- cancer
- antigen
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001588 bifunctional effect Effects 0.000 claims 46
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 102000000704 Interleukin-7 Human genes 0.000 claims 19
- 108010002586 Interleukin-7 Proteins 0.000 claims 19
- 238000006467 substitution reaction Methods 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000000178 monomer Substances 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 241000700605 Viruses Species 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 3
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- 229960002621 pembrolizumab Drugs 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000003964 Histone deacetylase Human genes 0.000 claims 2
- 108090000353 Histone deacetylase Proteins 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 2
- 241000579048 Merkel cell polyomavirus Species 0.000 claims 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229950007712 camrelizumab Drugs 0.000 claims 2
- 229940121420 cemiplimab Drugs 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 229950010773 pidilizumab Drugs 0.000 claims 2
- 229950007213 spartalizumab Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102220477126 C-X-C chemokine receptor type 4_Y12F_mutation Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000709687 Coxsackievirus Species 0.000 claims 1
- 241000724252 Cucumber mosaic virus Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241001466953 Echovirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims 1
- 241001524018 Human papillomavirus type 38 Species 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 241000701460 JC polyomavirus Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028729 Nasal cavity cancer Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000710799 Rubella virus Species 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 102000052622 human IL7 Human genes 0.000 claims 1
- 229940075628 hypomethylating agent Drugs 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000005746 immune checkpoint blockade Effects 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 201000000494 nasal cavity squamous cell carcinoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 claims 1
- 201000006958 oropharynx cancer Diseases 0.000 claims 1
- 208000007525 plasmablastic lymphoma Diseases 0.000 claims 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 102200006514 rs121913236 Human genes 0.000 claims 1
- 102220325989 rs1555376587 Human genes 0.000 claims 1
- 102200158840 rs33965337 Human genes 0.000 claims 1
- 102200121585 rs746702002 Human genes 0.000 claims 1
- 102200046712 rs752492870 Human genes 0.000 claims 1
- 102220061202 rs786203440 Human genes 0.000 claims 1
- 229940121497 sintilimab Drugs 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2020/086600 WO2021122866A1 (en) | 2019-12-17 | 2020-12-17 | Bifunctional molecules comprising an il-7 variant |
| EPPCT/EP2020/086600 | 2020-12-17 | ||
| EP21305462.0 | 2021-04-09 | ||
| EP21305462 | 2021-04-09 | ||
| EP21200350 | 2021-09-30 | ||
| EP21200350.3 | 2021-09-30 | ||
| PCT/EP2021/086471 WO2022129512A1 (en) | 2020-12-17 | 2021-12-17 | Bifunctional anti-pd1/il-7 molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023554097A JP2023554097A (ja) | 2023-12-26 |
| JP2023554097A5 JP2023554097A5 (https=) | 2024-12-25 |
| JPWO2022129512A5 true JPWO2022129512A5 (https=) | 2024-12-25 |
Family
ID=79024880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537140A Pending JP2023554097A (ja) | 2020-12-17 | 2021-12-17 | 二機能性抗ｐｄ１／ｉｌ－７分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240067727A1 (https=) |
| EP (1) | EP4263606A1 (https=) |
| JP (1) | JP2023554097A (https=) |
| KR (1) | KR20230129441A (https=) |
| AU (1) | AU2021402065A1 (https=) |
| CA (1) | CA3201729A1 (https=) |
| IL (1) | IL303745A (https=) |
| MX (1) | MX2023007301A (https=) |
| WO (1) | WO2022129512A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023281479A1 (en) * | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| WO2023281485A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| US20240424127A1 (en) * | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| CN118359730A (zh) * | 2023-01-17 | 2024-07-19 | 上海君赛生物科技有限公司 | 包含细胞因子的靶向型融合蛋白 |
| WO2026052654A1 (en) * | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| HUP0204475A2 (en) | 2000-02-11 | 2003-04-28 | Merck Patent Gmbh | Enhancing the circulating half-life of antibody-based fusion proteins |
| CA2551915C (en) * | 2003-12-30 | 2015-06-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Il-7 fusion proteins |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CA2902739C (en) | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| WO2017019846A1 (en) | 2015-07-30 | 2017-02-02 | Macrogenics, Inc. | Pd-1-binding molecules and methods use thereof |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| CN111491361B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| KR102561356B1 (ko) | 2016-09-14 | 2023-08-03 | 애브비 바이오테라퓨틱스 인크. | 항-pd-1 항체 및 이의 용도 |
| WO2019144945A1 (en) * | 2018-01-25 | 2019-08-01 | I-Mab | Anti-pd-l1 antibody and il-7 fusions |
| SG11202010163QA (en) * | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| US11505595B2 (en) * | 2018-04-18 | 2022-11-22 | Xencor, Inc. | TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains |
| CN112566801B (zh) | 2018-07-10 | 2024-03-01 | 依维柯股份公司 | 用于车辆的悬架 |
| EP4257199A3 (en) | 2018-12-21 | 2024-01-10 | Ose Immunotherapeutics | Humanized anti-human-pd-1 antibody |
| CN113614109A (zh) * | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| CN110256583B (zh) * | 2019-07-11 | 2022-05-20 | 中国科学院生物物理研究所 | 一种il-2突变体与抗体的融合蛋白及其应用 |
| AU2020406083A1 (en) * | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
-
2021
- 2021-12-17 KR KR1020237023523A patent/KR20230129441A/ko active Pending
- 2021-12-17 MX MX2023007301A patent/MX2023007301A/es unknown
- 2021-12-17 IL IL303745A patent/IL303745A/en unknown
- 2021-12-17 JP JP2023537140A patent/JP2023554097A/ja active Pending
- 2021-12-17 US US18/267,795 patent/US20240067727A1/en active Pending
- 2021-12-17 CA CA3201729A patent/CA3201729A1/en active Pending
- 2021-12-17 EP EP21831061.3A patent/EP4263606A1/en active Pending
- 2021-12-17 WO PCT/EP2021/086471 patent/WO2022129512A1/en not_active Ceased
- 2021-12-17 AU AU2021402065A patent/AU2021402065A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019530434A5 (https=) | ||
| JP2019533441A5 (https=) | ||
| JP2024119791A5 (https=) | ||
| IL269395B1 (en) | Immunoconjugations of anti–PD–1 antibody with IL–2 or IL–15 mutation | |
| JP2018516537A5 (https=) | ||
| FI3177643T5 (fi) | T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä | |
| RU2019141289A (ru) | АНТИ-SIRPα АНТИТЕЛА | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2021511064A5 (https=) | ||
| JP2021521275A5 (https=) | ||
| CA3086653A1 (en) | Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa) | |
| RU2018143439A (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент | |
| JP2020502233A5 (https=) | ||
| JP2012530496A5 (https=) | ||
| IL272747B2 (en) | Bispecific antibodies 1 + 2 | |
| JP2019500891A5 (https=) | ||
| RU2016133347A (ru) | Варианты fc-области с улучшенной способностью связываться с белком а | |
| JP2018525382A5 (https=) | ||
| JP2017506215A5 (https=) | ||
| JP2017504566A5 (https=) | ||
| JP2018526981A5 (https=) | ||
| JP2018517401A5 (https=) | ||
| JP2014503205A5 (https=) | ||
| JP2018522541A5 (https=) | ||
| WO2009068628A1 (en) | Constructs comprising single variable domains and an fc portion derived from lge. |